GANX Stock — Gain Therapeutics Inc.: Cash, EV, Pipeline

Share price

$1.76

Market cap

$76.8M

Cash

$13.1M

Enterprise value

$63.9M

Balance sheet

Cash	$13.1M
Debt	$0.2M
Net cash	$12.9M
Enterprise value	$63.9M
Basic shares	43.3M shares
Fully diluted shares	52.8M shares
Fully diluted market cap	$92.9M
Cash per share	$0.30

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading GANX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 11 - Sep 22	Low Dose GT-02287	Phase 2	Parkinson Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

rexaceract

Phase 1 · Active Modality: oral small molecule (allosteric GCase modulator)

Aliases GT-02287

Target GCase (glucocerebrosidase)

Partnerships Minoryx Therapeutics: exclusive worldwide license to Magellan platform/STAR compounds (Dec 2017); royalty-bearing; term 10 years post first commercialization

Indications

Parkinson's disease with GBA1 mutation (Phase 1)
Parkinson's disease without GBA1 mutation (Phase 1)

Catalysts

— Q3 2026
— October 2026

Status note Lead candidate; Phase 1a in healthy volunteers complete; Phase 1b in people with Parkinson's ongoing (Part 1 complete; Part 2 extension ongoing). FDA IND authorized June 2026 for Phase 2a.

GT-04686

Preclinical · Active Modality: oral small molecule (allosteric GCase modulator)

Target GCase (glucocerebrosidase)

Partnerships Minoryx Therapeutics: same Magellan platform license

Indications

not disclosed (Preclinical)

Status note Structurally distinct series of allosteric GCase modulators; ready to advance into IND-enabling studies. Indication not stated.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Low Dose GT-02287
Lead indication	Parkinson Disease
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07280299	Phase 2	Not yet recruiting	Sponsor	GANX	—	Parkinson Disease	—
NCT06732180	Phase 1	Recruiting	Sponsor	GANX	—	Parkinson Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Gain Therapeutics, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

GANX — Gain Therapeutics Inc.